Physician, DCR, OSCE, OGD, CDER, FDA Dr
The FDA itself is leveraging advances in AI to accelerate early-phase clinical trials, by extracting study data in real-time from electronic health records in a pilot announced this week involving Penn Medicine
Studies indicate that GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor) act as crucial "regulators" in maintaining human blood glucose balance and are important therapeutic targets for type 2 diabetes and obesity
The Phase III trials have been testing tirzepatide as monotherapy, as an add-on to other treatments, and against established glucose-lowering drugs in people with T2D, as well as a weight-loss agent in people with diabetes and obesity
Tirzepatide Once Weekly for the Treatment of Obesity. SURMOUNT-1 Trial
Firstly, to quantify the glycolytic activity of ILC2s ex-vivo, we analyzed their production of L-lactate, a terminal metabolite produced in the glycolysis pathway, noting that melatonin treatment precipitated a marked decrease in concentration ( Figure 5G )